Skip to main content

Table 3 One-year migraine improvement, in terms of modification in triptan use, among triptan-treated migraineurs with unmet medical needs (UMN) (both overall cohort and stratified for subtypes according to the average triptan dose units per month)

From: A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years

  Total Not Improved Improveda P value^
N N (%) N (%)
Overall UMN migraineurs (≥ 4 triptan dose units) 31,515 24,503 (77.7) 7012 (22.3)  
 At least one oral preventive therapy in the 1st year
  Yes 6121 4913 (80.3) 1208 (19.7) <.01
  No 25,394 19,590 (77.1) 5804 (22.9)
 At least one botulinum toxin injection in the 1st year
  Yes 191 161 (84.3) 30 (15.7) .03
  No 31,324 24,342 (77.7) 6982 (22.3)
pLF-EM (4–9 triptan dose units) 22,796 16,916 (74.2) 5880 (25.8)  
 At least one oral preventive therapy in the 1st year
  Yes 3856 2944 (76.3) 912 (23.7) <.01
  No 18,940 13,972 (73.8) 4968 (26.2)
 At least one botulinum toxin injection in the 1st year
  Yes 71 46 (64.8) 25 (35.2) .07
  No 22,725 16,870 (74.2) 5855 (25.8)
pHF-EM (10–14 triptan dose units) 5467 4725 (86.4) 742 (13.6)  
 At least one oral preventive therapy in the 1st year
  Yes 1278 1125 (88.0) 153 (12.0) .06
  No 4189 3600 (85.9) 589 (14.1)
 At least one botulinum toxin injection in the 1st year
  Yes 49 48 (98.0) 1 (2.0)  
  No 5418 4677 (86.3) 741 (13.7) .02
pCM (> 14 triptan dose units) 3252 2862 (88.0) 390 (12.0)  
 At least one oral preventive therapy in the 1st year
  Yes 987 844 (85.5) 143 (14.5) <.01
  No 2265 2018 (89.1) 247 (10.9)
 At least one botulinum toxin injection in the 1st year
  Yes 71 67 (94.4) 4 (5.6) .10
  No 3181 2795 (87.9) 386 (12.1)
  1. UMN Unmet medical need, pLF-EM Possible low frequency episodic migraine, pHF-EM Possible high frequency episodic migraine, pCM Possible chronic migraine
  2. ^ The differences of frequencies of migraine improvement between subjects with or without preventive therapy were tested through a chi-square test, considering statistically significant a p value <.01
  3. aImproved defined as reduction of ≥50% in average triptan dose units per month by comparing two subsequent years
\